Novo Holdings is poised to finalize its $16.5 billion acquisition of contract development and manufacturing organization (CDMO) Catalent, setting the stage for the largest biopharma merger of 2024. The companies announced on Saturday that they had cleared all regulatory hurdles, signaling that the transaction could be completed “in the coming days.”
According to Fierce Pharma, the buyout had faced scrutiny from lawmakers and consumer groups since its announcement in February. However, the Federal Trade Commission (FTC) ultimately declined to challenge the deal, per Bloomberg.
Catalent CEO Alessandro Maselli expressed optimism about the merger, stating that the support and resources from Novo Holdings would help Catalent “drive innovation and enhance offerings” for its customers and the patients it serves. Maselli emphasized that the partnership aligns with Catalent’s broader strategy to deliver value to stakeholders.
Related: Novo Holdings Secures EU Approval for $16.5 Billion Catalent Acquisition
Regulatory Concerns and Scrutiny
The acquisition attracted significant attention due to Catalent’s role in the manufacturing of GLP-1 drugs, which are central to treatments for diabetes and obesity. According to Fierce Pharma, one controversial element of the transaction involves Novo Nordisk’s plan to purchase three of Catalent’s fill-finish facilities from Novo Holdings for $11 billion once the deal is finalized. Critics have argued that this move could consolidate Novo Nordisk’s dominance in the GLP-1 market.
In October, U.S. Senator Elizabeth Warren, D-Massachusetts, raised concerns about the acquisition in a letter to then-FTC chair Lina Khan. Warren warned that the deal could stifle competition and lead to higher prices for patients reliant on GLP-1 inhibitor medications. Her concerns were echoed by trade unions and consumer advocacy groups, who submitted similar objections to the FTC shortly afterward.
Looking Ahead
Despite the controversy, the deal’s imminent closure signals a major shift in the biopharma landscape. For Novo Holdings, the acquisition bolsters its portfolio while positioning Catalent for growth in an increasingly competitive market. Meanwhile, the broader industry will be watching closely to see how the transaction impacts drug pricing and market competition.
Source: Fierce Pharma
Featured News
Uber and Lyft Face FTC Probe Over Alleged Collusion in NYC Pay Deal
Jan 30, 2025 by
CPI
Judge Certifies Class Action Suit Against Major Turkey Processors
Jan 30, 2025 by
CPI
US Justice Department Moves to Block HPE’s $14 Billion Juniper Acquisition
Jan 30, 2025 by
CPI
Ticketmaster Snubs UK Probe Into Dynamic Pricing
Jan 30, 2025 by
CPI
Federal Judge Clears Path for Texas-Led Antitrust Case Against Google
Jan 29, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Criminal Enforcement
Jan 23, 2025 by
CPI
The Antitrust Division’s Recent Work to Combat International Cartels
Jan 23, 2025 by
Emma Burnham & Benjamin Christenson
Information Sharing: The New Frontier of U.S. Antitrust Enforcement
Jan 23, 2025 by
Brian P. Quinn, Casey Kovarik & Michael Tubach
The Key Role of Guidelines on Exchanges of Information Among Competitors and the Divergent Transatlantic Paths
Jan 23, 2025 by
Rosa Abrantes-Metz & Albert Metz
Leniency, Whistleblowers, and Compliance
Jan 23, 2025 by
Richard Powers, Tara O’Malley & Cory Gordon